Neural crest tumor (Neuroblastoma) is a malignant neoplasm that develops from neural crest cells, which are the precursors of neurons and glia. These tumors are most common in children, especially those under five years of age, and can occur in a variety of sites, including the adrenal glands, spine, and cervical region. Neuroblastoma can present as a large lesion, often characterized by aggressive behavior and high metastatic activity. Symptoms can range from local manifestations to systemic manifestations, such as pain, weight loss, and symptoms associated with compression, such as paralysis or organ dysfunction.
History of the disease and interesting historical facts
Neuroblastoma was first reported in the early 20th century, when doctors began to recognize the connection between tumors arising from nerve tissue and their aggressive nature. In 1910, another researcher, Dr. William Hauser, described cases of tumors in children, but the term “neuroblastoma” was not introduced until 1923 by Dr. Waldemar Pehrson. Over time, neuroblastoma attracted the attention of various specialists, including oncologists and pediatricians, which contributed to modern research and treatment methods. Since the 1940s, clinical trials have been underway to develop new treatments, including chemotherapy and radiotherapy. Interesting facts about the disease include that 60% cases of neuroblastoma occur in the abdominal region and are often considered one of the most common extracerebral tumors in children.
Epidemiology
Neuroblastoma is one of the most common malignant tumors in pediatric practice. According to statistics, there are 10.5 cases of neuroblastoma per 1 million children under 15 years of age. This tumor is most often diagnosed in children under 5 years of age, with the peak incidence occurring at 18 months. More than 95% cases occur in children under 10 years of age, and among those affected, there is a predominance of boys over girls in a ratio of 1.5:1.
Although neuroblastoma can occur in all ethnic groups, its incidence may vary by race and geographic factors. Several studies have shown that previous family history of neuroblastoma may contribute to an increased statistical likelihood of developing the disease. This highlights the importance of early detection and monitoring of this pathology in risk groups.
Genetic predisposition to this disease
Research has confirmed the presence of a genetic predisposition to neuroblastoma, based on which several genes and genetic mutations have been identified. Among the most significant genes are:
- MYCN – this oncogene is associated with a high degree of tumor aggressiveness and poor prognosis
- TP53 – mutations in this gene can lead to disruption of apoptosis and cell division processes
- ALK – mutations in this gene have been identified in some patients with neuroblastoma
- ETV6 – its genetic changes have also been linked to neuroblastoma.
In addition, it is known that a family history of neuroblastoma and other neuroectodermal tumors may indicate the possible heredity of this pathology, although the vast majority of cases of the disease are sporadic.
Risk factors for the development of this disease
There are various risk factors that may contribute to the development of neuroblastoma. The main ones include:
- Genetic factors – the presence of mutations in certain genes, such as MYCN and ALK
- Age – the most vulnerable age for the development of neuroblastoma is up to 5 years
- Gender - Boys are at greater risk than girls
- Environmental factors – exposure to certain chemicals and radiation may increase the risk
- Immune disorders – a weakened immune system can contribute to the development of tumors
Given the multifactorial nature of this disease, further research is needed to fully understand the mechanisms of its development and the impact of various factors.
Diagnosis of this disease
Neuroblastoma diagnostics includes several stages and methods that help determine the presence of a tumor, its location and stage. The main diagnostic methods include:
- Clinical examination and history – identification of obvious symptoms such as abdominal pain, fatigue, weight change.
- Laboratory tests – determination of markers of tumor activity, such as the level of metanephrines in the blood and urine.
- Radiological examinations – ultrasound, MRI, CT, which help to visualize the tumor and assess its spread.
- Biopsy – obtaining a tissue sample for histological examination.
Differential diagnosis includes exclusion of other diseases such as tumors of other organs, lymphomas and medulloblastomas. For accurate diagnosis and assessment of tumor aggression, a combination of data from several methods is necessary.
Treatment
Treatment of neuroblastoma is a complex approach that includes many methods. The main treatment areas are:
- General treatment – may include monitoring and support of the patient’s condition, especially in cases of small and low-grade tumors.
- Pharmacological treatment – chemotherapy is used, which can significantly reduce the size of the tumor and reduce symptoms.
- Surgical treatment – surgery is often the main method of removing a tumor, especially when localized within one organ.
- Other treatments – immunotherapy and radiation therapy may be used in combination with other methods to improve treatment outcomes.
List of medications used to treat this disease
Currently, there are several main groups of drugs used in the treatment of neuroblastoma:
- Cyclophosphamide
- Doxorubicin
- Vincristine
- Irineotecan
- Melphalan
- Topotecan
- Gemspirone
- Tasigna
Medicines can be combined to achieve maximum effectiveness and reduce side effects.
Disease monitoring
Neuroblastoma monitoring includes regular examinations and monitoring of the patient's condition. The main aspects of monitoring are:
- Control stages – every 3-6 months during the first two years after treatment, then less frequently.
- Prognosis – largely depends on the stage of the disease and the morphological characteristics of the tumor; a favorable prognosis is observed in 50-70% low-risk patients.
- Complications – possible relapses, metastases and side effects from treatment.
This approach allows for timely detection of relapses and minimization of possible complications.
Age-related features of the disease
Neuroblastoma can manifest itself with varying intensity depending on the age of the patient. Infants and young children often have more aggressive tumors, while older children have less aggressive forms of neuroblastoma.
Children under 1 year of age usually have a better prognosis and higher chances of a full recovery. At the same time, in children over 10 years of age, the incidence is already much lower, but, unfortunately, cases with more advanced stages of the tumor are observed more often.
Questions and Answers
- What is neuroblastoma? — Neuroblastoma is a malignant tumor that develops from neural crest cells, most often observed in children.
- What symptoms may indicate the presence of neuroblastoma? — The main symptoms include abdominal pain, weight loss, fatigue, and in severe cases, compression syndromes.
- What is the life expectancy after being diagnosed with neuroblastoma? — The prognosis varies depending on the stage and aggressiveness of the tumor, with a favorable outcome observed in 50-70% cases.
- What are the main treatments for neuroblastoma? — Treatment includes chemotherapy, surgery, radiotherapy and immunotherapy.
- Is the patient's age taken into account when determining the treatment method? — Yes, the patient’s age is one of the key factors influencing the choice of treatment strategy and prognosis.
